Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18459234 | 0.81 | TSHR (0.38) | TSHRTDP1 | |
| SCHEMBL6285811 | 0.80 | TSHR (0.55) | TSHRTDP1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27807441 | 0.78 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL10496895 | 0.78 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL25588756 | 0.78 | TSHR (0.35) | TSHRTDP1ALDH1A1 | |
| SCHEMBL14528615 | 0.78 | CYP2D6 (0.39) | TSHRTDP1 | |
| SCHEMBL20374323 | 0.78 | TSHR (0.44) | TSHRTDP1 | |
| SCHEMBL13130164 | 0.75 | TSHR (0.40) | TSHRTDP1ALDH1A1 | |
| SCHEMBL21086576 | 0.73 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL10496797 | 0.73 | TSHR (0.32) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | BIOSYNTHIS (FR) | 2024-05-02 | — | — | US | claimed |
| EP-2829555-B1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-05-16 | — | — | EP | claimed |
| US-9315602-B2 | Method for producing olefin polymer | MITSUI CHEMICALS, INC. (JP) | 2016-04-19 | — | — | US | claimed |
| US-12616728-B2 | Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same | SUPER CRITICAL IP, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260041617-A1 | COSMETIC COMPOSITION APPLICABLE TO THE SKIN AND BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2026-02-12 | — | — | US | disclosed |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | BIOSYNTHIS (FR) | 2025-06-19 | — | — | US | disclosed |
| US-20250177263-A1 | LIPSTICK COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2025-06-05 | — | — | US | disclosed |
| US-20250170037-A1 | EYE MAKEUP COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2025-05-29 | — | — | US | disclosed |
| US-20250152646-A1 | SOLVENTS, METHODS, AND SYSTEMS FOR ISOLATING CANNABINOIDS FROM PLANTS EXTRACTS OR FROM SYNTHETIC PATHWAYS | NOEL ARMAND J (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4496553-A1 | COSMETIC COMPOSITION APPLICABLE TO THE SKIN AND BASED ON A VOLATILE MIXTURE OF ALKANES | Biosynthis (FR) | 2025-01-29 | — | — | EP | disclosed |
| EP-4486287-A1 | LIPSTICK COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES | Biosynthis (FR) | 2025-01-08 | — | — | EP | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| US-4804654-A | INSECTICIDES, MITICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616728-B2 | Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same | CNR2, CNR1, SCD | TSHR 2794/4885TDP1 4427/4885ALDH1A1 4135/4885 |
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | ALKBH2, ABHD12, FAAH2 | TSHR 3034/4885TDP1 2123/4885ALDH1A1 938/4885 |
| US-20260041617-A1 | COSMETIC COMPOSITION APPLICABLE TO THE SKIN AND BASED ON A VOLATILE MIXTURE OF ALKANES | CUTA, AP2M1, LBR | TSHR 612/4885TDP1 1620/4885ALDH1A1 134/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | TSHR 4374/4885TDP1 1215/4885ALDH1A1 645/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | TSHR 4420/4885TDP1 2045/4885ALDH1A1 2002/4885 |
| US-20250197341-A1 | METHOD FOR INHIBITING CRYSTALLISATION | FASN, SCD5, NFKB2 | TSHR 3901/4885TDP1 3078/4885ALDH1A1 3607/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | TSHR 3766/4885TDP1 630/4885ALDH1A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.